Human α-synuclein accumulates in dopaminergic neurons as intraneuronal inclusions, Lewy bodies, which are characteristic of idiopathic Parkinson's disease (PD). Here, we suggest that modulation of the functional activity of the dopamine transporter (DAT) by α-synuclein may be a key factor in the preferential degeneration of mesencephalic dopamine (DA)-synthesizing neurons in PD. In cotransfected Ltk -, HEK 293, and SK-N-MC cells, α-synuclein induced a 35% decrease in [ 3 H]DA uptake. Biotinylated DAT levels were decreased by 40% in cotransfected cells relative to cells expressing only DAT. DAT was colocalized with α-synuclein in mesencephalic neurons and cotransfected Ltk -cells. Coimmunoprecipitation studies showed the existence of a complex between α-synuclein and DAT, in specific rat brain regions and cotransfected cells, through specific amino acid motifs of both proteins. The attenuation of DAT function by α-synuclein was cytoprotective, because DA-mediated oxidative stress and cell death were reduced in cotransfected cells. The neurotoxin MPP + (1-methyl-4-phenylpyridinium), oxidative stress, or impairment of cell adhesion ablated the α-synuclein-mediated inhibition of DAT activity, which caused increased uptake of DA and increased biotinylated DAT levels, in both mesencephalic neurons and cotransfected cells. These studies suggest a novel normative role for α-synuclein in regulating DA synaptic availability and homeostasis, which is relevant to the pathophysiology of PD.
These observations suggest that α-synuclein may represent a common molecular bond between seemingly unrelated neurodegenerative disorders. In addition, rare autosomal dominant forms of familial PD are associated with Ala30Pro (A30P) and Ala53Thr (A53T) missense mutations in α-synuclein (14, 15) , which are not found in idiopathic PD (16, 17) , but no direct connection with the pathological process has yet been established. A prerequisite of α-synuclein neuropathy is its transformation into insoluble protofibrils (8, 18) composed of β sheets and amyloid-like filaments (19) (20) (21) before its aggregation and accumulation in LBs. Several experimental conditions, including overexpression of the protein, presence of the A30P or A53T mutations, exposure to neurotoxins, oxidative factors, and transition metals, induce α-synuclein aggregation, both in vivo and in vitro, through procedures that remain poorly understood (22) (23) (24) (25) (26) (27) .
How α-synuclein may be implicated in the pathophysiological process of PD is far from obvious. First, several studies suggest that α-synuclein per se is not neurotoxic but instead may contribute to neuronal growth and plasticity (22) (23) (24) (28) (29) (30) . Moreover, α-synuclein was shown in some studies to protect against oxidative stress and apoptosis in both transfected cells (31) (32) (33) (34) (35) (36) (37) and rat models (30, (38) (39) (40) . Its absence in α-syn −/− mice resulted in some pathological features and functional deficits in the nigrostriatal dopamine (DA) system, such as reduced vesicular storage of DA and increased DA release into the synapse (40) . Second, α-synuclein and its mRNA are widely and abundantly distributed throughout the brain (0.1% total brain protein) (22) , including areas that do not form part of the neurodegenerative cellular cluster of PD.
A first clue relating α-synuclein to the parkinsonian neurodegenerative process is that aberrations in the structure and solubility and overexpression of α-synuclein may occur preferentially in DA-producing cells. An interesting report documenting the stabilization of α-synuclein protofibrils by oxidized DA (41) lends credence to the concept of a relationship between abnormally high cellular levels of DA and aggregation of α-synuclein. Other work suggesting that α-synuclein regulates DA homeostasis through modulation of DA pathways of biosynthesis (42, 43) , reuptake (44) (45) (46) , and vesicle storage or extracellular release (47) (48) (49) prompted us to investigate normative and toxic roles of α-synuclein, by examining its interactions with the dopamine transporter (DAT). The DAT is a member of a large family of Na + -and Cl − -dependent transporters (50, 51) , which was recently identified as a protein binding partner of α-synuclein (44) . Indeed, DAT is present at high levels only in DA-synthesizing neurons of the mesencephalic areas, which preferentially degenerate in PD (52) . The DAT, by mediating the reuptake of DA, is the foremost determinant for the recycling and inactivation of DA released into the synaptic cleft by DA-producing neurons and is the primary means by which dopaminergic neurotransmission and synaptic strength are regulated. The importance of DAT function in the control of synaptic availability of DA suggests that its own regulation may be a crucial component in the maintenance of dopaminergic neurotransmission, because enhanced DAT activity would not only increase intracellular levels of DA but also increase production of reactive oxygen species (ROS) within the dopaminergic cell. However, the molecular mechanism (or mechanisms) by which the activity of DAT is regulated remains an enigma, despite studies suggesting possible participation of kinases, with rapid shuttling of the transporter to or away from the plasma membrane (53, 54) .
Here, we show that α-synuclein forms a complex with DAT in both rat brain tissues and transfected cells, which regulates the amount of DAT at the plasma membrane. In basal situations, α-synuclein tends to markedly decrease DA uptake by DAT as well as decrease DAmediated oxidative stress and cell death. Disruption of cell adhesion by trypsin, elicitation of oxidative stress by H 2 O 2 , or exposure to the parkinsonian syndrome-linked neurotoxin MPP + (1-methyl-4-phenylpyridinium) causes relief of α-synuclein-mediated inhibition of DAT function, with increased recruitment of the transporter to the plasma membrane, enhancing uptake of DA with accelerated cell death, upon intracellular oxidation of DA. These novel findings highlight a previously unknown role for α-synuclein in the normal regulation of DAT function-dynamic modulation of dopaminergic neurotransmission and DA content in neurons-while providing a heuristic framework in which to view the roles of these proteins in the preferential targeting of DA-producing neurons in PD and parkinsonian syndromes.
MATERIALS AND METHODS

cDNAs and minigenes constructs
Human α-synuclein (a gift from T. Dawson, Johns Hopkins University, Baltimore, MD) and human DAT (hDAT) cDNA (a gift from F. Liu and H. B. Niznik, University of Toronto, Canada) constructs were subcloned into the mammalian expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA) by using the EcoRI restriction site. Constructs encoding specific α-synuclein and hDAT segments (minigenes; see Fig. 6A and 6E, respectively) were generated by PCR with oligonucleotides directed to specific areas of cDNA incorporating KpnI and XhoI restriction sites, stop codons in the 3'-oligonucleotides, and methionine initiation codons in the 5'-oligonucleotides, and these were subcloned into pcDNA3.1. The subcloned cDNAs were resequenced to detect any spurious PCR-generated errors. Plasmid DNAs were propagated in Escherichia coli DH5 and purified from overnight bacterial cultures by using the Endo-Free Plasmid Mega kit from QIAGEN (catalog no. 12381, QIAGEN, Valencia, CA) according to the QIAGEN Plasmid Purification Handbook.
Cell culture and transfection
Ltk
-fibroblasts, human neuroblastoma-derived SK-N-MC cells, and HEK 293 human embryonic kidney cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Cellgro 10-013-CM, BioSource International, Camarillo, CA) supplemented with 10% FBS (Sigma, St. Louis, MO), antibiotics, and 2 mM L-glutamine, at 37°C and in 5% CO 2 . For the experiments, cells grown in 12 wells (10 5 cells seeded/well) were transiently transfected (1 µg of DNA/10 5 cells) by the DEAE dextran/chloroquine method as described previously (45, 46) and used 48 h after transfection (termed here in situ transfection). For batch transfections, cells were transfected in T185 flasks (1 µg of DNA/10 5 cells), detached with trypsin 6 h after transfection, seeded into individual 12-well dishes, and used after 48 h of growth in DMEM plus 10% FBS (termed here batch transfection).
Primary rat mesencephalic cultures
Mesencephalons from 18-day-old rat embryos were isolated, mechanically dissociated in icecold HBSS (Sigma), and grown (seeding density 600-800 cells/mm 2 ) in 24 wells in Neurobasal medium (Invitrogen) with 2% (vol/vol) B27 supplement (Invitrogen) on glass coverslips precoated with poly-L-ornithine (15% w/v in borate buffer 0.1 M pH 8.4; MW 30,000-70,000; Sigma) and laminin (3 µg/ml in PBS; Sigma) for 6 days, as described by Brewer et al. (55) .
Coimmunoprecipitation (co-IP) studies and Western blotting
Rat tissues (250 mg; Zivic Laboratories, Zelienople, PA), or transfected Ltk -cells (1-2 × 10 7 ) were solubilized with 1% sodium cholate (Sigma), as described previously (56) . In some experiments, lysates from rat tissues were mixed 1:1 (v/v) with lysates of either mocktransfected cells or Ltk -cells transfected with α-synuclein minigenes alone (0.5-1 mg/ml protein/lysate). To the soluble extracts (200-400 µl/assay tube, 1-1.5 mg/ml protein), the following antiserum was added (1:100): DAT polyclonal (Chemicon AB5802 for transfected cells, Chemicon, Temecula, CA; Chemicon AB1591P for rat tissues) or α-synuclein polyclonal (Chemicon AB5334P), or rabbit nonimmune sera (5 µg of protein). Immune complexes were precipitated with protein A-Sepharose beads (CL-4B, Amersham Biosciences, Piscataway NJ); pellets were washed five times and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting. Blots were probed with antibodies (1:1000) for either DAT (Chemicon MAB 369) or α-synuclein (BD Biosciences monoclonal antibody 610787, BD Biosciences Clontech, Palo Alto, CA). Proteins were visualized by using peroxidase-conjugated secondary antibodies (1:8000; Santa Cruz, Santa Cruz, CA) and enhanced chemiluminescence (Amersham, Arlington Heights, IL). DAT was detected as a major band with an M r value of about 82 kDa; α-synuclein had an M r value of about 23 kDa, consistent with the known molecular sizes reported in the literature.
Cell trypsinization and treatment, and oxidative stress measurement
In some experiments, mild trypsinization of the cells was carried out, to interfere with cell adhesion on substrate. To do that, 24 h after transfection, cells were rinsed twice with PBS, submitted to 0.1% trypsin for 30 s, and rinsed with PBS three times (mild trypsinization), or cells were just rinsed five times with PBS (controls), and then they were grown for another 24 h before being analyzed, by immunocytochemistry, or for DA uptake, oxidative stress, and cell death (see below). Similarly, mesencephalic cultures were carefully rinsed twice with PBS, submitted to 0.1% trypsin for 30 s without cell detachment, rinsed three times with PBS (mild trypsinization) (or just rinsed five times with PBS [controls]), and grown for another 24 h in Neurobasal medium with 2% (vol/vol) B27 supplement.
In experiments designed to study the effect of oxidative stress, transfected cells or primary neurons were washed twice with Dulbecco's PBS (D-PBS) and were maintained for 12 h in DMEM culture medium without serum. Then, concentrated stock solutions (500 ×) of MPP + (in dimethyl sulfoxide) or H 2 O 2 (freshly and extemporarily prepared in H 2 O; Sigma) were diluted inside the CO 2 incubator in the serum-free culture medium without a medium change to obtain final concentrations in the wells of 10- O, and homogenized, and lysates were cleared by centrifugation in a microfuge. Levels of ROS were determined by measuring the fluorescence emission at 525 nm of the supernatants with a fluorescent microplate reader (fluorescence excitation at 475 nm). In some experiments, oxidative stress was assessed by measuring nitrite levels, a stable byproduct of nitric oxide, by the Griess method using sodium nitrite standards (Sigma), as described previously (46, 57) . Cell death was determined by cell counting with the trypan blue (Sigma) exclusion test, as described by the manufacturer's protocol. 
Immunofluorescence and confocal microscopy
Forty-eight hours after transfection (cell lines) or 6 days after seeding (primary neurons), cells were fixed with 3% paraformaldehyde (Calbiochem, San Diego, CA) and were permeabilized with 0.1% Triton X-100 (Sigma) in D-PBS plus 0.5% (wt/vol) bovine serum albumin (BSA), as described previously (58) . Cells were incubated with primary anti-DAT antiserum (1:500; Chemicon AB5802 for human DAT; Chemicon AB1591P for rat DAT) and with primary anti-α-synuclein antiserum (1:500; BD Biosciences monoclonal antibody 610787) for 12 h at 4°C, and for 2 h at room temperature with Alexa Fluor 568-conjugated secondary antibody (for DAT) and Alexa Fluor 488-conjugated secondary antibody (for α-synuclein) (1:500; Molecular Probes, Eugene, OR). Cells were analyzed with a Nikon Eclipse E800 inverted fluorescence microscope or a Leica TCS4D confocal microscope. Successive fluorescence acquisitions were performed by using the 488-and the 568-nm laser lines, after selection of the fluorescence with appropriate double-fluorescence dichromic mirror and bandpass filters. No cross-detection between the two fluorescent emissions was noticed.
Biotinylation and quantification of DAT at the plasma membrane
Two days after transfection (Ltk -) or 6 days after seeding (primary mesencephalic neurons), cells were washed in ice-cold PBS pH 8.5 containing 1 mM MgCl 2 (PBS-M), after which they were incubated on ice for 30 min with gentle shaking with a freshly prepared solution of EZ-link NHS-biotin (Pierce, Rockford, IL; 0.5 mg/ml in PBS-M). The reaction was stopped by removing the biotin solution, washing the cells with ice-cold PBS-M, and incubating for 10 min on ice with gentle agitation in 50 mM glycine (in PBS-M). The cells were rinsed with PBS-M, collected in ice-cold lysis buffer (50 mM Tris buffer pH 7.6 containing 500 mM NaCl, 250 mM sucrose, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM dithiothreitol, 1 mM EDTA, 1 mM EGTA, 1% wt/vol sodium cholate, 10 µg/ml each leupeptin and pepstatin, 500 µM phenylmethylsulfonyl fluoride [PMSF], and 0.2 mM sodium orthovanadate) and were rocked for 1 h at 4°C. Lysates were cleared by centrifugation for 20 min at 18,500g at 4°C. Protein concentration was equalized with dilution buffer (10 mM Tris buffer pH 7.4 containing 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 10 µg/ml each leupeptin and pepstatin, 500 µM PMSF, and 0.2 mM sodium orthovanadate). Then, anti-DAT polyclonal antibody (1:100; Chemicon AB5802 for hDAT; Chemicon AB1591P for rat DAT), anti-α-synuclein polyclonal antibody (1:100; Chemicon AB5334P), or nonimmune serum (5 µg protein; rabbit or sheep nonimmune sera from Chemicon) was added to the diluted extracts (1-1.5 mg/ml protein) for immunoprecipitation, as described above. Blots were preincubated for 1 h with 5% (wt/vol) BSA in TTBS (10 mM Tris buffer pH 7.4, 150 mM NaCl, and 0.05% Tween-20) and were probed for 2 h with horseradish peroxidase (HRP)-conjugated avidin (1:1000 in TTBS plus 5% [wt/vol] BSA; Pierce) to quantify biotin-bound DAT, which is a reliable index of the amount of DAT present at the plasma membrane.
In parallel, reverse experiments were carried out, and solubilized protein samples (about 1 mg/ml protein) were affinity purified with Sepharose beads conjugated to NeutrAvidin (Pierce), according to the manufacturer's protocol. After an overnight incubation at 4°C with agitation, beads were washed five times with dilution buffer. Bound proteins were solubilized by heating the beads for 10 min at 65°C in 2× Laemmli buffer and were subjected to SDS-PAGE and Western blotting. Blots were probed for DAT (1:1000, Chemicon MAB 369 monoclonal antibody), and proteins visualized as described above. To ensure that equal expression levels of DAT protein were present in each sample (biotinylated plus nonbiotinylated protein), we verified that similar levels of hDAT or α-synuclein protein could be immunoprecipitated from each sample by their specific antisera, or by directly analyzing the whole cell lysates on Western blots, as described above.
Data analysis
Each experimental measurement was performed in quadruplicate and is the mean ± SE of four to six experiments. Kinetic parameters of [ 3 H]DA uptake were calculated by linear regressions of the Eadie-Hoffstee plots and were confirmed by a nonlinear regression program on KaleidaGraph (version 3.0.8 D, Abelbeck Software, Reading, PA). Statistical significance was obtained via Instat Statistical Software (GraphPad Software, San Diego, CA), by variance analysis with Fisher's test, with * as P < 0.05 and ** as P < 0.01.
RESULTS
α-Synuclein diminished DAT activity
To examine the functional interaction between hDAT and α-synuclein, we directed the expression of these proteins in Ltk -mouse fibroblasts by in situ transfection (Fig. 1A) . At the concentration of DNA used (1 µg DNA/1 × 10 5 cells), the protein levels of both α-synuclein (57) and hDAT (C. Wersinger et al., unpublished observations) expressed in the Ltk -cells approximated that seen in adult substantia nigra and in mesencephalic neurons. In these cells, the translocation velocity (V max ) of hDAT-mediated cellular [ 3 H]DA uptake was significantly (P<0.05) decreased (Fig. 1A ) by 35% (from 2.3 ± 0.043 to 1.5 ± 0.04 pmol/min/10 5 cells in hDAT-transfected and hDAT + α-synuclein-transfected cells, respectively) in the presence of α-synuclein, relative to cells expressing hDAT alone (Fig. 1A) . The decrease in uptake was not due to any changes in the K m (2.6 ± 0.1 vs. 2.7 ± 0.1 µM in hDAT-transfected and hDAT + α-synuclein-transfected cells, respectively) of the hDAT for DA (Fig. 1A) . The attenuation of hDAT activity by α-synuclein was also observed in cotransfected HEK 293 and SK-N-MC neuroblastoma cells ( 5 cells in hDAT-transfected and hDAT + α-synucleintransfected cells, respectively; P<0.05), which was also not due to changes in K m values (1.60 ± 0.09 vs. 1.66 ± 0.13 µM). These combined data confirm that the attenuation of hDAT activity by α-synuclein was independent of the cell type in which these two proteins were coexpressed. In all cells, hDAT-mediated uptake of DA was completely inhibited (>95%) by 10 µM INDT, the transporter blocker (Fig. 1A) , whereas in mock-transfected cells (vector DNA) or in cells expressing α-synuclein alone, there was no uptake of DA (data not shown). Similar observations were made for HEK 293 and SK-N-MC cells (data not shown).
The diminished response of hDAT by α-synuclein was not due to changes in protein expression levels of either hDAT or α-synuclein upon coexpression in transfected cells and comparison of Western blots of singly transfected and cotransfected Ltk -cells showed similar protein levels of both hDAT and α-synuclein (Fig. 1C) . [ 3 H]DA basal efflux was negligible, whether or not cells expressed α-synuclein, in all experimental conditions used in this study (data not shown).
Trypsin treatment reversed the effect of α-synuclein on hDAT
In an earlier study (44) , increased DA uptake was reported in Ltk -cells cotransfected with α-synuclein and hDAT, at odds with our current data. A significant difference between the two studies may be due to methods of transfection, because in the earlier study DEAE-dextran batchtransfected cells were trypsinized and reseeded after the transfection procedure (batch transfection) (44) , whereas for our studies the transfection was conducted in individual plates without trypsinization and replating (in situ transfection method). We tested for this and found that, with the batch transfection method, α-synuclein increased hDAT activity (>45%, Fig. 2A 2C ), relative to cells singly transfected with hDAT. Because the degree of α-synuclein-mediated inhibition of hDAT activity depends on the amount of α-synuclein expressed in the cells (45, 46) , the expression of α-synuclein was assessed and compared by Western blotting after batch transfection (44) and after the in situ transfection method described in this study, by using the same amount of α-synuclein and hDAT DNA for transfection (1 µg of DNA/10 5 cells) (Fig. 2D) . In all instances, batch-transfected trypsinized Ltk -cells expressed much lower (40%) levels of α-synuclein compared with in situ-transfected cells, without any changes in overall expression of hDAT. No significant difference in the V max of DA uptake in DAT singly expressing cells was evidenced in trypsinized cells (batch transfected) (data not shown) and nontrypsinized cells (transfected by the in situ method) (Fig. 1) , which further suggests that the two different methods used for transfection may be responsible for the differential modulation of hDAT activity observed in the two situations. Because trypsin affects cell adhesion, we examined batchtransfected cells by immunoconfocal analyses and found a marked absence of α-synucleinexpressing focal adhesion points (data not shown), which was also seen in cells that had been briefly subjected to mild trypsinization (0.1% trypsin, 30 s, Fig. 2E ). These data suggest that the lack of attenuation of hDAT function by α-synuclein (44) may be linked to its low expression at focal adhesion points, possibly implying a role for the cytoskeleton matrix in these modulatory processes. In all subsequent studies described below, the in situ method of transfection was used.
Colocalization of α-synuclein and DAT in transfected cells and neurons
The modulation of hDAT function by α-synuclein implicated some degree of colocalization in the transfected cells. To test that suggestion, immunocytochemical labeling of hDAT and α-synuclein was analyzed by confocal microscopy of Ltk -cotransfected cells. Analysis showed that α-synuclein immunoreactivity was essentially spread over the cytoplasm, but also with significant labeling at the plasma membrane (Fig. 3A, B, and C) . By contrast, hDAT immunolabeling was detected at the plasma membrane, although a significant amount was present in intracellular compartments, probably in the endoplasmic reticulum and Golgi apparatus. A significant overlap in the hDAT and α-synuclein labeling was evidenced at both the plasma membrane and intracellular reticular compartments, which demonstrated partial colocalization of these proteins that varies from one cell to another (Fig. 3C ).
To be physiologically relevant, the interaction between DAT and α-synuclein requires that these two proteins be coexpressed within the same neuron, in a natural condition. Although both DAT and α-synuclein are known to be present in substantia nigra (SN) (52, 59) , direct evidence for the colocalization of these proteins within individual neurons is lacking. Immunocytochemical studies were conducted with rat primary mesencephalic neurons, in which coexpression of DAT with α-synuclein was seen in each and every neuron (data not shown). Immunoconfocal analyses of individual mesencephalic neurons showed clear and substantial colocalization of the two proteins within the neuron (Fig. 3D and 3E ). DAT immunolabeling was mainly located at the plasma membrane of the soma and axonal processes of the neurons, although a significant amount of the DAT was also localized in intracellular compartments, as in transfected cells. Moreover, DAT labeling was concentrated in nerve terminals and in varicosities along axonal processes. The α-synuclein immunoreactivity was generally more widespread than that of DAT, especially in neuronal perikarya, but some labeling was also located at the plasma membrane and in varicosities all along the axonal processes. Substantial α-synuclein labeling was present in the axon growth cone of the neuron (Fig 3, arrows D and E) , without colocalization with DAT, in agreement with a putative role of this protein in neuronal growth and plasticity (22-24, 28, 29) .
Presence of α-synuclein reduced the amount of DAT at the plasma membrane
Because no change in the K m of DA uptake by DAT was evidenced in the presence or absence of α-synuclein in cells, it appeared very likely that the recruitment of DAT to the plasma membrane may be a major factor for modulation of DAT activity by α-synuclein. To examine the hypothesis of a regulation of plasma membrane recruitment of DAT, changes in the amount of the transporter at the plasma membrane were measured after covalent biotinylation of the cell surface in Ltk -cells expressing only hDAT or coexpressing hDAT and α-synuclein, 2 days after transfection, as described in Materials and Methods. After cell homogenization and lysis, hDAT was immunoprecipitated and the proportion of biotin-labeled protein was quantified by Western blotting for the two conditions of transfected cells. Reverse experiments were carried out, in which biotinylated proteins were isolated first on streptavidin-agarose beads and corresponding Western blots were probed with the anti-DAT antibody. In both cases, the amount of biotinbound hDAT was significantly lower in cells in which α-synuclein was present than in cells in which only hDAT was expressed (Fig. 4) . Expression levels of total hDAT (biotinylated plus nonbiotinylated) were similar in lysates of cells expressing only hDAT and in lysates of cells coexpressing hDAT and α-synuclein, as assessed by the hDAT immunoreactivity present in the pellets after immunoprecipitation with hDAT antibodies (Fig. 4) . Thus, a role of α-synuclein may be to modulate the shuttling of DAT between intracellular vesicular compartments and the plasma membrane.
Protein-protein interactions of α-synuclein and DAT in endogenously expressing rat brain tissues and cotransfected Ltk-cells
To further assess the mechanisms underlying the negative modulation of hDAT activity by α-synuclein, reciprocal co-IP assays were conducted, followed by identification of the proteins present in the immunopellets. Negative controls were lysates of cells singly transfected with either α-synuclein or hDAT. The hDAT antibody recognized its own antigen protein, of about 82 kDa, corresponding to the known molecular size of hDAT, in both cotransfected and singly transfected cells (Fig. 5A, upper panel) . In addition, the hDAT antibodies coimmunoprecipitated a protein of about 23 kDa, corresponding to the known molecular size of α-synuclein, in cotransfected cells but not cells transfected with α-synuclein alone (Fig. 5A, upper panel) . In reciprocal studies, the α-synuclein antibodies coimmunoprecipitated the hDAT protein from cotransfected cells and not from cells singly transfected with hDAT alone, in addition to immunoprecipitating their specific antigenic protein (Fig. 5A, lower panel) .
Although α-synuclein and DAT interact in cotransfected Ltk -cells, the ability of these proteins to form a stable complex in brain regions endogenously expressing these proteins is not known. To test for this, we conducted co-IP studies with lysates prepared from the following rat brain regions: SN, ventral tegmental area (VTA), and striatum. In all these brain tissues, α-synuclein antibodies coimmunoprecipitated the DAT (Fig. 5B, upper panel) . In reciprocal co-IP studies, the DAT antibody coimmunoprecipitated the α-synuclein protein from these tissues (Fig. 5B, lower panel). These data confirm that in rat brain areas coexpressing these proteins, the proteins can interact with each other to form stable complexes through direct protein-protein interactions, which indicates that such DAT-α-synuclein complexes are likely to have physiological relevance.
DAT and α-synuclein physically interacted through specific motifs of both proteins
To directly identify the amino acid motifs that participate in the formation of the α-synucleinhDAT protein complex, we cotransfected Ltk -cells with minigenes encoding different structural regions of α-synuclein (Fig. 6A) . Co-IP studies showed that only the minigene α-syn2 encoding the nonβ-amyloid component (NAC) domain of α-synuclein, but not minigenes α-syn1 or α-syn3, by competing with the full-length α-synuclein, prevented its interaction with hDAT (Fig.   6B ). The lack of formation of a complex was not due to interference of the α-syn2 product with either DAT or α-synuclein, because both proteins were immunoprecipitated by their own specific antibodies (Fig. 6B) . The functional consequences of these findings were ascertained through [ 3 H]DA uptake studies, by using cells cotransfected with full-length hDAT and the α-synuclein minigenes (Fig. 6C) . Neither the amino lipid binding α-helix (α-syn1) nor the acidic cytoplasmic tail (α-syn3) could modulate hDAT-mediated uptake of [ 3 H]DA. Instead, the decrease in functional activity of hDAT was absolutely dependent on the presence of the NACencoding domain (α-syn2) of α-synuclein and, moreover, was of the same magnitude as that observed with the full-length α-synuclein. These data indicate that only the NAC domain of α-synuclein participates in both complex formation and modulation of hDAT activity.
To assess whether α-synuclein-DAT interactions in rat brain proceed through similar amino acid motifs of α-synuclein, lysates were prepared from Ltk -cells transfected with α-syn1, α-syn2, or α-syn3. We speculated that lysates derived from such cells, containing discrete amino acid motifs of the α-synuclein domains, when mixed with rat brain lysates, may competitively inhibit the complex formation between DAT and α-synuclein. As indexed by co-IPs, neither α-syn1 nor α-syn3 could block formation of a complex between hDAT and α-synuclein, which indicates their lack of participation in such a complex (data not shown). Instead, the interaction between α-synuclein and DAT depended solely on the presence of α-syn2 (encoding the NAC domain of α-synuclein), which, by competing with the full-length α-synuclein in lysates from VTA, SN, and striatum, prevented its interaction with DAT (Fig. 6D) . The lack of formation of a complex was not due to interference of the α-syn2 product with either DAT or α-synuclein, because both proteins were immunoprecipitated by their own specific antibodies. These observations clearly indicate that α-synuclein physically interacts in situ through its NAC domain with the DAT in endogenously expressing systems of rat brain, which confirms the physiological relevance of our findings in cotransfected Ltk -cells.
To similarly identify the amino acid motifs on hDAT that participate in the protein-protein interactions with α-synuclein, we conducted co-IPs after cotransfection of α-synuclein with fulllength hDAT, in the presence or absence of minigenes encoding different regions of the cytoplasmic tail of hDAT (Fig. 6E ). In the presence of hDAT1 or hDAT3, but not hDAT2, formation of the protein-protein complex between hDAT and α-synuclein was completely prevented (Fig. 6F) . Moreover, hDAT1 and hDAT3, but not hDAT2, could completely block the negative modulation of hDAT activity by α-synuclein (Fig. 6G ).
α-Synuclein-mediated regulation of DAT activity dictated the consequences of DA-induced oxidative stress and cell death
We examined the functional consequence of α-synuclein-mediated inhibition of hDAT activity by measuring DCF emission fluorescence and cell death, to assess ROS and cytotoxicity, respectively, after exposure of cotransfected Ltk -cells to increasing concentrations of DA. We also measured nitrite levels, a stable byproduct of free radical generation. In mock-transfected cells, exposure of these cells to DA resulted in a 20-30% decrease in cell viability (Fig. 7A) , which was accompanied by a corresponding 3.2-to 6-fold increase in nitrite levels (data not shown) and a 3.4-to 8.5-fold increase in DCF fluorescence emission (Fig. 7B) because of extracellular autoxidation of DA to free radicals, as evidenced by ablation, in the presence of 200 µM of the antioxidant SMBS, of the increase in cell death (Fig. 7A ), nitrite production (data not shown), and DCF emission fluorescence (Fig. 7B) .
In hDAT-transfected cells, DA greatly enhanced cell death (by about 37% and 70%, with 50 µM and 200 µM DA, respectively; Fig. 7A ), nitrite production (7-and 10-fold, with 50 µM and 200 µM DA, respectively; data not shown), and DCF fluorescence (8-and 18-fold, with 50 µM and 200 µM DA respectively, Fig. 7B ), compared with mock-transfected cells. This increased response in hDAT-transfected cells was blocked by INDT, with restoration of cell viability, nitrite production (data not shown), and DCF emission fluorescence to levels seen in mocktransfected cells, which indicated that the enhancement was due entirely to increased uptake of DA by hDAT into the cells. In hDAT + α-synuclein cotransfected cells, ROS (Fig. 7B) , nitrite production (data not shown), and cell death (Fig. 7A) were sharply and significantly (P<0.05) reduced, consistent with diminished hDAT-mediated uptake of DA by the cells (Fig. 7A and B) . Thus, the additional presence of α-synuclein reduced hDAT-mediated cell death by 10% and 22%, with 50 µM and 200 µM DA, respectively (Fig. 7A) . Nitrite production (data not shown) was attenuated by 2.2-and 3-fold, whereas ROS levels ( Fig. 7B) were decreased by 2.1-and 5.4-fold, with 50 µM and 200 µM DA, respectively, in hDAT-α-synuclein coexpressing cells, compared with cells transfected with hDAT alone. Again, INDT reduced these indices to levels seen in mock-transfected cells, which indicated a requirement for hDAT-mediated uptake of DA and its subsequent intracellular autoxidation in these processes. In cells singly transfected with α-synuclein, cell death (Fig. 7A) , nitrite production (data not shown), and ROS production (Fig.   7B) were the same as those in mock-transfected or INDT-treated cells, which indicated that α-synuclein alone did not induce oxidative stress or cell death. These results suggest a cytoprotective effect of α-synuclein against DA-induced oxidative stress and apoptosis that may be mediated, in part, through modulation of DA intracellular levels through the negative modulation of DA uptake by hDAT. Cytoprotective effects of α-synuclein against oxidative stress and apoptosis have already been described (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) .
Oxidative stress reversed the effect of α-synuclein on hDAT
Because oxidative stress is linked to PD etiology, the effects of the potent oxidant H 2 O 2 (1 µM) and MPP + (10-1000 nM), a known causative agent of PD, were studied. In Ltk -cells coexpressing hDAT and α-synuclein, brief pretreatment (30 min) with low doses of MPP + or H 2 O 2 reversed, in a dose-dependent manner, α-synuclein-mediated modulation of hDAT function (Fig. 8A) , accompanied by increased ROS (Fig. 8B) and cytotoxicity (Fig. 8C) 8B) , or cell viability (Fig. 8C) (Fig. 8D ), ROS production (Fig. 8E) , and cytotoxicity (Fig. 8F) were also seen after pretreatment for 30 min of primary mesencephalic neurons, but at lower concentrations of MPP + , which attests to the physiological relevance of our findings. Thus, [ 3 H]DA uptake was increased with pretreatment with 10-50 nM MPP + or 1 µM H 2 O 2 , and this increase was of a similar magnitude to that seen in Ltk -cells. At higher concentrations of MPP + (≥100 nM), there was diminished uptake of DA (Fig. 8D) . In both Ltk -cotransfected cells and primary mesencephalic neurons, mild treatment with trypsin mimicked the effects of lower concentrations of MPP + and H 2 O 2 , by relieving the α-synuclein-mediated inhibition of DAT activity and accelerating DA uptake ( Fig. 8A and 8D) , with increased ROS production and cytotoxicity (data not shown). Pretreatment of the neurons for 30 min with 50 nM MPP + or mild trypsinization (0.1% trypsin; 30 s) of the neurons increased the levels of biotinylated DAT, an index of plasma membrane-associated DAT levels (Fig. 8G) . Similar results were observed in transfected Ltk -cells (data not shown). Pretreatment with MPP + or mild trypsinization did not change the total DAT (biotinylated plus nonbiotinylated) and α-synuclein expression levels in neurons, as assessed by the DAT immunoreactivity of the immunopellets after immunoprecipitation with anti-DAT antibodies (Fig. 8G) . Taken together, these data suggest that, in these neurons, as in Ltk -cells, the transporter activity is under negative modulation, probably because of the presence of a significant amount of α-synuclein.
DISCUSSION
The results presented here highlight a previously unknown role of α-synuclein in the modulation of the functional activity of DAT, a role that may be central to the physiological maintenance of dopaminergic tone and neurotransmission. Our findings describe a nontoxic role for α-synuclein, which underscores a novel mechanism through which a cytoprotective function of α-synuclein is manifest in dopaminergic cells. These observations are supported by the normal situation that exists in brain, where α-synuclein has a prominent role in neuroprotection, neuronal growth, and plasticity (22, 24, 28, (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) . Moreover, α-synuclein and its mRNA are widely distributed throughout the brain (22, 27, 59) , including areas that do not form part of the neurodegenerative cellular cluster of PD or parkinsonian syndromes. That these proteins interact with one another in DAT-expressing brain regions was evidenced by our co-IP studies of SN, VTA, and striatum and was verified via immunocytochemistry of single mesencephalic neurons. This is important because interactions between DAT and α-synuclein were up to now demonstrated only in transfected cells (44) (45) (46) . Yet, in normal brain, these α-synuclein/DAT-enriched regions do not degenerate a priori, nor do they spontaneously develop LBs, except in diseased states. Together, these results support a normative role for α-synuclein that is not cytotoxic. This contention is corroborated by the observations, with α-synuclein −/− mice, of some pathological features and functional deficits in the nigrostriatal DA system, such as reduced vesicular storage of DA and increased DA release into the synapse (40) .
In an earlier study, Lee et al. (44) suggested that α-synuclein coexpression with DAT increased [ 3 H]DA uptake, which caused increased cell death on exposure to DA, in agreement with our results using the batch transfection method. However, these findings do not fit well with a probable role of α-synuclein in neuroprotection (30) (31) (32) (33) (34) (35) (36) (37) , and in neuronal growth and plasticity (22) (23) (24) (28) (29) (30) . In addition, although we confirmed that DAT and α-synuclein interact both in brain lysates and in cotransfected cells through the same region identified by Lee et al. (the NAC domain of α-synuclein; 44), we observed a decrease in DAT activity instead of an increase, together with decreased levels of DAT at the cell surface, in the presence of α-synuclein, when we used the in situ transfection method. A possible source for discrepancies between these findings and those described earlier (44) may depend on the magnitude of protein-protein interactions that stabilize the formation of the complex of α-synuclein and DAT. In the previous studies (44), co-IPs showed low levels of α-synuclein or DAT coimmunoprecipitated by DAT or α-synuclein antibodies, respectively. In our hands, the in situ transfection method resulted in much larger amounts of proteins present in the coimmunoprecipitates, indicating a greater degree of protein-protein interactions, which could then dictate the functional outcome of such interactions. Indeed, our data show that a prerequisite for the negative modulation of DAT activity is the formation of strong protein-protein interactions between specific amino acid motifs on these two proteins.
Because the previous studies were also performed with the DEAE-dextran method of transfection and may have been done with batch transfections, followed by dissociation of cells with trypsin before subculture of cells into individual wells, such trypsinization could have an adverse effect on DAT-α-synuclein functional interactions and membrane recruitment of DAT, as revealed by the experiments presented here. Indeed, we observed that even mild trypsinization of either cotransfected Ltk -cells or mesencephalic neurons can transform the negative effect of α-synuclein on DA uptake into an increase in DAT activity, in agreement with the data of Lee et al. (44) . Mild trypsinization also increased the levels of DAT present at the cell surface in both mesencephalic neurons and cotransfected cells. Besides the experimental interest of this observation, it may suggest that impairment of cell adhesion occurring within the brain in the course of the neurodegenerative process may be an aggravating factor of the disease.
One phenomenon that may account for the modulation of DA uptake by α-synuclein seems to be the recruitment of DAT at the plasma membrane. Indeed, we showed by means of a plasma membrane biotinylation technique that the presence of α-synuclein elicited a reduction in the amount of DAT at the cell surface, with the in situ transfection method. Further studies are required to better understand the precise mechanisms of the shuttling of DAT from and to the plasma membrane, but recently Gosavi et al. (60) also observed that overexpression of α-synuclein in COS-7 cells decreased targeting of the DAT to the plasma membrane. The proposed mechanism is somewhat different because these authors showed that α-synuclein formed prefibrillar aggregates inducing Golgi fragmentation and an impairment of DAT maturation and transport into the secretory pathway. Our confocal microscopy analyses failed to reveal any Golgi fragmentation or α-synuclein aggregation in our cotransfected Ltk -cells, but a common mechanism may have been put into play in the two situations. In particular, interactions between the microtubule network and the vesicular components of the secretory pathway may well be a plausible link between α-synuclein and the trafficking of DAT in the cell compartments.
It is worth noting that some factors strongly linked to the genesis of PD and parkinsonian syndromes in humans and animal models, namely, oxidative stress and MPP + , also disrupt the α-synuclein-mediated negative regulation of DAT activity, which accelerate DAT-mediated uptake of DA and cause enhanced ROS production and neurotoxicity. Pretreatment of mesencephalic neurons or cotransfected cells with very low doses of MPP + also increased the levels of DAT at the cell surface, as assessed by biotinylation experiments of cell surface proteins. The DAT is the major target by which both DA and MPP + are taken up into nigrostriatal cells, and although MPP + -mediated dysfunctions of the mitochondrial respiratory chain are well established (61) (62) (63) , our data suggest that MPP + may in addition hamper the ability of α-synuclein to negatively regulate hDAT activity, which would cause increased DA re-uptake by the dysregulated transporter, with concomitant increases in free radical production and degeneration of the nerve termini. These findings give further credence to our hypothesis that disruption of the normative role of α-synuclein on DAT activity may be a key component of the neurodegenerative process of PD and parkinsonian syndromes. The expression of DAT in DA-producing neurons and its localization at nerve terminals are instrumental for the selective uptake of compounds such as MPP + in the SN. This will confer the necessary selectivity associated with the preferential degeneration of dopaminergic neurons in PD and parkinsonian syndromes. A similar facilitory role of α-synuclein in PD-linked neurodegeneration may be linked to its recently observed modulatory effect on tyrosine hydroxylase activity, the key enzyme in DA biogenesis (42, 43) , and to its modulatory effect, induced by overexpression, on the vesicular storage of DA, which causes decreases in the activity and expression levels of the vesicular monoamine transporter VMAT2 (47) (48) (49) . Thus, a primary function of presynaptic α-synuclein in dopaminergic neurons may be the regulation of DA homeostasis.
Our results thus provide unique insights into the possible means by which DAT function is modulated. In this regard, it should be noted that the molecular mechanism (or mechanisms) by which the activity of DAT is regulated remains an enigma, despite studies suggesting possible participation of kinases (53, 54) , with rapid shuttling of the transporter to or away from the plasma membrane (50, 54, 64) . The evidence presented here suggests that coexpression of DAT with α-synuclein causes greater accumulation of the transporter protein within the cytoplasm of Ltk-cells, with increased recruitment of the transporter protein away from the plasma membrane, so that fewer DATs are present at the cell surface. Because α-synuclein can directly interact with cytoskeletal proteins such as tubulin (65, 66) or with proteins associated with the cytoskeleton such as tau (67) , MAP1B (68), MAP2 (69), synphilin-1 (70, 71) , and torsinA (72), we speculate that α-synuclein could act as an important intermediary between the cytoskeleton and DAT in the trafficking of the transporter between plasma membrane and intracellular compartments of secretion or endocytosis. Whatever the mechanisms of the modulation would be, it is clear that α-synuclein, DAT, and DA-induced oxidative stress are each important components of the cascade of events that precipitates the destruction of dopaminergic neurons in PD and parkinsonian syndromes. cells; in situ transfection method), and cell surface proteins were labeled with biotin, as described in Materials and Methods. Biotinylated hDAT levels were assessed, both by immunoprecipitating total hDAT (second gel from top) and looking for the fraction of total hDAT that was biotinylated with avidin-HRP (top gel), and by immunoprecipitating the total pool of biotinylated proteins with NeutrAvidin and quantifying the participation of hDAT, with anti-hDAT antibodies, to the overall pool of biotinylated proteins (third gel from top). As a control, α-synuclein levels were assessed after immunoprecipitation from lysates of cells expressing only hDAT or from cells coexpressing hDAT and α-synuclein (bottom gel). Data shown represent three experiments. with full-length hDAT and α-synuclein in the absence (control) or presence of minigenes α-syn1 to α-syn3 were used in co-IP studies. α-syn2 blocked the co-IP of hDAT with α-synuclein without altering the ability of these proteins to be immunoprecipitated by their own specific antibodies. C) In Ltk -cells expressing full-length hDAT and either the fulllength α-synuclein (control) or the different α-synuclein minigenes (1 µg of DNA for each/10 5 cells; in situ transfection method), only those minigenes encoding the NAC domain of α-synuclein could mimic the inhibitory effects of the fulllength α-synuclein. Averages of six experiments are shown. *P < 0.05, significantly different from hDAT singly transfected cells. D) A direct physical interaction between DAT and α-synuclein was also mediated through the NAC domain of α-synuclein, in various DAT-expressing brain tissues. Sodium cholate lysates were prepared from SN, VTA, and striatum, and from either pcDNA3.1 (mock) or α-syn2 DNA singly transfected Ltk -cells. Lysates from rat tissues were mixed 1:1 (vol/vol) with lysates of mock-transfected Ltk -cells (lanes labeled −) or lysates of α-syn2 singly transfected Ltk -cells (lanes labeled +) (0.5-1 mg/ml protein for both types of lysates). Co-IP studies were conducted as described in Materials and Methods. DAT and α-synuclein protein present in coimmunoprecipitates were detected by Western blotting, after IP with either antisera against DAT (IP DAT) or α-synuclein (IP Syn). Data shown represent at least four independent studies. E) Schematic of constructs encoding the hDAT cytoplasmic tail. F) Lysates from Ltk-cells cotransfected with fulllength hDAT and α-synuclein in the absence (control) or presence of minigenes hDAT1 to hDAT3 (1 µg of DNA for each/10 5 cells; in situ transfection method) were used in co-IP studies. The minigenes hDAT1 and hDAT3 did not alter the levels of either hDAT or α-synuclein immunoprecipitated by their own antibodies but did block co-IP of hDAT with α-synuclein. G) Minigenes hDAT1 and hDAT3 competed with α-synuclein in Ltk -cells transfected with full-length α-synuclein and hDAT (1 µg of DNA for each/10 5 cells), to relieve inhibition of hDAT activity mediated by α-synuclein. The averages of six experiments are shown. *P < 0.05, significantly different from hDAT singly transfected cells. 20 µM for neuronal cultures). Means ± SE of four to six experiments are shown; **P < 0.01 and *P < 0.05, significantly different compared with hDATtransfected cells. G) Levels of biotinylated DAT in mesencephalic neurons after pretreatment for 30 min with 50 nM MPP + or vehicle (0.2% H 2 O; control; C), or 24 h after mild trypsinization (0.1% trypsin, 30 s; T). Cell surface proteins were labeled with biotin, as described in Materials and Methods. Biotinylated DAT levels were assessed, both by immunoprecipitating total DAT (biotinylated plus nonbiotinylated; second gel from top) and looking for the fraction of total DAT that was biotinylated with avidin-HRP (top gel), and by immunoprecipitating the total pool of biotinylated proteins with NeutrAvidin and quantifying the participation of DAT, with anti-DAT antibodies, to the overall pool of biotinylated proteins (third gel from top). As a control, α-synuclein levels were assessed after immunoprecipitation from the neuronal lysates (bottom gel), to confirm that expression levels of α-synuclein were not changed by processes described in the Materials and Methods. Data shown represent three experiments.
